Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.48 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 5/20 | 0.53 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
| ▸ | SI | P14410 | 1/20 | 0.48 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73416 | 0.97 | TSHR (0.56) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL1396293 | 0.91 | — | — | |
| Hydrochloric Acid SCHEMBL28087018 | 0.89 | TSHR (0.50) | TSHRTET2RECQLHSD17B10GAA | |
| Hydrochloric Acid SCHEMBL2016633 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL15855934 | 0.86 | TSHR (0.46) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL2303378 | 0.86 | TSHR (0.52) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL12329903 | 0.86 | GAA (0.55) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL2361759 | 0.85 | TSHR (0.50) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL5199404 | 0.84 | TSHR (0.43) | TSHRTET2RECQLHSD17B10GAA | |
| SCHEMBL800951 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | UNIV EMORY (US) | 2022-09-29 | — | — | US | disclosed |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | EMORY UNIVERSITY (US) | 2022-07-12 | — | — | US | disclosed |
| US-20210274789-A1 | Antimicrobial Surface Treatment | KODE BIOTECH LTD (NZ) | 2021-09-09 | — | — | US | disclosed |
| CN-107847617-B | Metal tricarbonyl complexes containing substituted iminodiacetic acid ligands and their use as radiotracers | 爱默蕾大学 | 2021-08-31 | — | — | CN | disclosed |
| EP-3221337-B1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2021-08-04 | — | — | EP | disclosed |
| CN-108463466-B | Glycolipid compounds and their use in the treatment of tumors | 艾佳尔免疫有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20210139540-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | BOVIN NICOLAI VLADIMIROVICH (RU) | 2021-05-13 | — | — | US | disclosed |
| US-10919941-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2021-02-16 | — | — | US | disclosed |
| US-10781235-B2 | Multivalent ligand-lipid constructs | BOVIN NICOLAI VLADIMIROVICH (RU) | 2020-09-22 | — | — | US | disclosed |
| CN-111320567-A | Reactive light stabilizer compound and liquid crystal composition containing same | 东进世美肯株式会社 | 2020-06-23 | — | — | CN | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
| EP-2201025-A1 | FUNCTIONAL LIPID CONSTRUCTS | Bovin, Nicolai (RU) | 2010-06-30 | — | — | EP | disclosed |
| WO-2010043230-A1 | MULTILIGAND CONSTRUCTS | BOVIN NIKOLAI VLADIMIROVICH (RU) | 2010-04-22 | — | — | WO | disclosed |
| WO-2009048343-A1 | FUNCTIONAL LIPID CONSTRUCTS | BOVIN NICOLAI (RU) | 2009-04-16 | — | — | WO | disclosed |
| US-7473688-B2 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-20070195309-A1 | PHOTOCHROMIC PROBES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-08-23 | — | — | US | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2007033175-A1 | INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-03-22 | — | — | WO | disclosed |
| EP-0835259-A1 | IODINE-CONTAINING PEPTIDES AND THEIR USE AS X-RAY CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-15 | — | — | EP | disclosed |
| WO-1996040760-A2 | IODINE-CONTAINING PEPTIDES AND THEIR USE AS X-RAY CONTRAST MEDIA | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139540-A1 | MULTIVALENT LIGAND-LIPID CONSTRUCTS | PHOSPHO1, MGLL, LPAR6 | GAA 3415/4885CA2 4337/4885TSHR 1851/4885 |
| US-20220306663-A1 | Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope Tracers | SLC16A8, S100A8, FGF23 | GAA 1863/4885CA2 79/4885TSHR 338/4885 |
| US-20070195309-A1 | PHOTOCHROMIC PROBES | ORAI1, TRPC1, STIM1 | GAA 2877/4885CA2 5/4885TSHR 4075/4885 |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | GAA 2482/4885CA2 4210/4885TSHR 4299/4885 |
| US-10919941-B2 | Functional lipid constructs | CETP, LCAT, LIPA | GAA 1088/4885CA2 2207/4885TSHR 1794/4885 |
| US-20210274789-A1 | Antimicrobial Surface Treatment | CD68, ARG1, CLTB | GAA 737/4885CA2 3235/4885TSHR 2031/4885 |
| US-11384106-B2 | Metal tricarbonyl complexes comprising substituted iminodiactic acid ligands and uses as radioisotope tracers | SLC16A8, S100A8, FGF23 | GAA 1863/4885CA2 79/4885TSHR 338/4885 |
| US-10781235-B2 | Multivalent ligand-lipid constructs | PHOSPHO1, MGLL, LPAR6 | GAA 3415/4885CA2 4337/4885TSHR 1851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.